JP2022531231A5 - - Google Patents

Info

Publication number
JP2022531231A5
JP2022531231A5 JP2021564498A JP2021564498A JP2022531231A5 JP 2022531231 A5 JP2022531231 A5 JP 2022531231A5 JP 2021564498 A JP2021564498 A JP 2021564498A JP 2021564498 A JP2021564498 A JP 2021564498A JP 2022531231 A5 JP2022531231 A5 JP 2022531231A5
Authority
JP
Japan
Prior art keywords
sequence
cells
seq
optionally
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564498A
Other languages
English (en)
Japanese (ja)
Other versions
JP7717619B2 (ja
JP2022531231A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/030818 external-priority patent/WO2020223537A1/en
Publication of JP2022531231A publication Critical patent/JP2022531231A/ja
Publication of JP2022531231A5 publication Critical patent/JP2022531231A5/ja
Application granted granted Critical
Publication of JP7717619B2 publication Critical patent/JP7717619B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564498A 2019-05-01 2020-04-30 Cd8改変t細胞療法を使用するがんの治療のための組成物及び方法 Active JP7717619B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962841753P 2019-05-01 2019-05-01
US201962841748P 2019-05-01 2019-05-01
US62/841,753 2019-05-01
US62/841,748 2019-05-01
PCT/US2020/030818 WO2020223537A1 (en) 2019-05-01 2020-04-30 Compositions and methods for the treatment of cancer using a cdb engineered t cell therapy

Publications (3)

Publication Number Publication Date
JP2022531231A JP2022531231A (ja) 2022-07-06
JP2022531231A5 true JP2022531231A5 (cg-RX-API-DMAC7.html) 2023-05-12
JP7717619B2 JP7717619B2 (ja) 2025-08-04

Family

ID=73029470

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564500A Pending JP2022530653A (ja) 2019-05-01 2020-04-30 Tet2改変t細胞療法を使用するがんの治療のための組成物及び方法
JP2021564498A Active JP7717619B2 (ja) 2019-05-01 2020-04-30 Cd8改変t細胞療法を使用するがんの治療のための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021564500A Pending JP2022530653A (ja) 2019-05-01 2020-04-30 Tet2改変t細胞療法を使用するがんの治療のための組成物及び方法

Country Status (11)

Country Link
US (4) US20210085720A1 (cg-RX-API-DMAC7.html)
EP (2) EP3953379A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022530653A (cg-RX-API-DMAC7.html)
KR (2) KR20220005050A (cg-RX-API-DMAC7.html)
CN (1) CN113748127B (cg-RX-API-DMAC7.html)
AU (2) AU2020264484B2 (cg-RX-API-DMAC7.html)
CA (2) CA3151385A1 (cg-RX-API-DMAC7.html)
IL (2) IL287643A (cg-RX-API-DMAC7.html)
MX (2) MX2021013218A (cg-RX-API-DMAC7.html)
SG (2) SG11202111532SA (cg-RX-API-DMAC7.html)
WO (3) WO2020223478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856769A4 (en) * 2018-09-28 2022-08-17 Memorial Sloan Kettering Cancer Center IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
PH12022550548A1 (en) * 2019-09-06 2023-11-20 Crispr Therapeutics Ag Genetically engineered t cells having improved persistence in culture
AU2021261011A1 (en) * 2020-04-24 2022-11-10 Pact Pharma, Inc. Methods of determining gene editing efficiencies in cells
WO2022109277A1 (en) * 2020-11-20 2022-05-27 Pact Pharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
US20250032540A1 (en) * 2020-12-14 2025-01-30 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2022140361A1 (en) * 2020-12-22 2022-06-30 Ludwig Institute For Cancer Research Ltd Genetically engineered lymphocytes for adoptive cell therapy
US20240108652A1 (en) * 2021-02-18 2024-04-04 University Of Florida Research Foundation, Incorporated Enhancing metabolic fitness of t cells to treat cancer
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2022242644A1 (zh) * 2021-05-18 2022-11-24 赛斯尔擎生物技术(上海)有限公司 修饰细胞的方法
JP2024523014A (ja) * 2021-06-11 2024-06-25 パクト ファーマ インコーポレイテッド 細胞製剤を査定する方法
WO2023049733A2 (en) * 2021-09-21 2023-03-30 The University Of Chicago Methods and composition using patient-derived autologous neoantigens for treating cancer
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
US20230313138A1 (en) 2021-10-28 2023-10-05 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
CN114373511B (zh) * 2022-03-15 2022-08-30 南方医科大学南方医院 基于5hmC分子标志物检测的肠癌模型及肠癌模型构建方法
WO2023212507A1 (en) * 2022-04-26 2023-11-02 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CA3262766A1 (en) 2022-07-28 2024-02-01 Stemcell Technologies Canada Inc. Polynucleotides encoding bound antigens and their uses
CN120202302A (zh) * 2022-09-19 2025-06-24 埃门多生物公司 Ctla4双等位基因敲除
KR20250073155A (ko) * 2022-09-19 2025-05-27 에멘도바이오 인코포레이티드 Faslg의 이중 대립유전자 녹아웃
JP2025529540A (ja) * 2022-09-19 2025-09-04 エメンドバイオ・インコーポレイテッド Tet2の両アレルノックアウト
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
KR20260033048A (ko) 2023-07-03 2026-03-10 네오이뮨텍, 인코퍼레이티드 이종이합체 fc 분자 및 이의 용도
JP2026526545A (ja) * 2023-07-31 2026-08-07 テ-クニフェ ゲーエムベーハー 強化型キメラヒトcd8共受容体、強化型キメラヒトcd8共受容体をコードする核酸、対応するベクター、核酸またはベクターが形質導入された単離t細胞、これらを調製するキット、および、対応する医薬組成物、および疾患を有する患者を治療する方法
WO2025045752A1 (en) * 2023-08-25 2025-03-06 T-Knife Gmbh Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US20020127594A1 (en) * 2000-06-22 2002-09-12 Gearing David P. Don-1 gene and polypeptides and uses therefor
US6355412B1 (en) * 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
EP3858379A1 (en) * 2013-11-21 2021-08-04 Autolus Limited Cell
EP3215521B1 (en) * 2014-11-06 2025-10-08 University of Maryland, Baltimore Cd8 and t cell receptor variants and methods of using same in modulating immune cell responses
MX2017012829A (es) * 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
MA44907A (fr) * 2015-09-11 2018-07-18 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
CA2999070A1 (en) * 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
AU2016374253B2 (en) * 2015-12-18 2021-10-21 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
WO2017176769A1 (en) * 2016-04-04 2017-10-12 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
KR102397771B1 (ko) * 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
KR20190130608A (ko) * 2017-03-22 2019-11-22 노파르티스 아게 면역종양학을 위한 조성물 및 방법
RU2019133286A (ru) 2017-03-22 2021-04-22 Новартис Аг Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью
US11512287B2 (en) * 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
CN111032686B (zh) * 2017-06-30 2024-05-14 莱顿大学医学中心附属莱顿教学医院 血液恶性肿瘤的治疗
JP2020532987A (ja) * 2017-09-08 2020-11-19 ポセイダ セラピューティクス,インコーポレイティド キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法
EP3703712A4 (en) * 2017-10-30 2021-09-22 PACT Pharma, Inc. EDITING PRIMARY CELL GENES
WO2019136335A1 (en) * 2018-01-05 2019-07-11 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
KR20200138334A (ko) 2018-04-02 2020-12-09 팩트 파마, 인크. 펩티드-MHC comPACT
US20210317184A1 (en) * 2018-09-05 2021-10-14 GlaxoSmithKline Intellectual Property Devolopment Limited T cell modification
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
IL316576A (en) 2019-02-12 2024-12-01 Pact Pharma Inc Preparations and methods for identifying antigen-specific T cells
KR20220029584A (ko) * 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용

Similar Documents

Publication Publication Date Title
JP7008350B2 (ja) Car発現ベクター及びcar発現t細胞
US20250101080A1 (en) Chimeric antigen receptors and uses thereof
JP6612963B2 (ja) 腫瘍抗原を直接認識するために組換えt細胞レセプターを使用するための組成物及び方法
JP2025090690A (ja) 抗kras-g12d t細胞受容体
JP6359520B2 (ja) B細胞成熟抗原を標的指向するキメラ抗原受容体
JP2024138280A5 (cg-RX-API-DMAC7.html)
JP2021530999A5 (cg-RX-API-DMAC7.html)
US20110280894A1 (en) Her2/neu specific t cell receptors
US20250250319A1 (en) Chimeric transmembrane polypeptides comprising a tgf beta receptor extracellular domain, a transmembrane domain and an interleukin receptor 2 intracellular signalling domain and its use in therapy
JP2024519515A5 (cg-RX-API-DMAC7.html)
EP4613762A1 (en) Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8
JP2021525534A5 (cg-RX-API-DMAC7.html)
JP2025508050A (ja) Cd70指向性がん免疫療法のための多重遺伝子編集細胞
WO2020041501A1 (en) Immunotherapy targeting kras or her2 antigens
CN113286815B (zh) 间皮素特异性t细胞受体及其在免疫治疗中的应用
EP4061385A1 (en) A method for redesign and expansion of nk92 cells for use in immunotherapy
JP7518915B2 (ja) Cd3融合タンパク質およびその使用
WO2018033544A1 (en) Method for the generation of t cell hybridoma for cloning and analysis of receptors using engineered measles virus fusogenic glycoproteins
EP4328239A1 (en) Immunotherapeutics based on magea1-derived epitopes
TW202548008A (zh) 治療腫瘤之組合物和方法
WO2025193663A2 (en) Compositions and methods for treating neoplasia
HK40060048A (en) T cell receptors specific for mesothelin and their use in immunotherapy
HK40109914A (en) Anti-egfrviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition containing said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptide
CN117813384A (zh) 嵌合抗原受体、表达前述受体的细胞、包含前述细胞的医药组合物、前述细胞的制造方法、及包含编码前述嵌合抗原受体的碱基序列的多核苷酸或载体
RU2020142686A (ru) Специфичные к muc16 химерные антигенные рецепторы и их применения